TNGX
Tango Therapeutics Inc

604
Loading...
Loading...
News
all
press releases
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 0.00% and -48.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
IGM Biosciences (IGMS) delivered earnings and revenue surprises of +626.67% and +4,388.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 61.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·1mo ago
News Placeholder
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tango Therapeutics (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 75.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·2mo ago
News Placeholder
5 Biotech Stocks with Highly Anticipated Pending Results
Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.
Stocktwits Contributor·3mo ago
News Placeholder
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Zacks·3mo ago
News Placeholder
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial...
Business Wire·10mo ago
News Placeholder
Tango Therapeutics to Participate in Upcoming Investor Conferences
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara...
Business Wire·1y ago

Latest TNGX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.